• DOI:10.1167/iovs.12-11032
• Corpus ID: 11670330

Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.

@article{Amparo2013SafetyAE,
  title={Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.},
  author={Francisco Amparo and Zahra Sadrai and Yiping Jin and Bel{\'e}n Alfonso-Bartolozzi and Haobing Wang and Hasanain Shikari and Joseph B. Ciolino and James Chodosh and Ula V. Jurkunas and Debra A. Schaumberg and Reza Dana},
  journal={Investigative ophthalmology \& visual science},
  year={2013},
  volume={54 1},
  pages={
          537-44
        }
}

• Francisco Amparo, Zahra Sadrai, +8 authors R. Dana
• Published 17 January 2013
• Medicine
• Investigative ophthalmology & visual science

PURPOSE
To evaluate the safety and efficacy of topical pazopanib in the treatment of corneal neovascularization (CNV).

METHODS
Twenty eyes of 20 patients with stable CNV were enrolled in a prospective, open label, noncomparative study and treated with topical pazopanib 0.5% for 3 weeks, and followed for 12 weeks. The primary endpoint was to determine the tolerability and safety of topical pazopanib in the treatment of CNV defined by the occurrence of ocular and systemic adverse events during the study. The secondary endpoint was to evaluate the effect of topical pazopanib on the reduction of (1) neovascular area (NA), defined as the area of the corneal vessels themselves, (2) invasion area (IA), defined as the fraction of the total cornea into which the vessels extend, (3) vessel length (VL), defined as the mean measurement of the extent of vessels from end to end, and (4) vessel caliber (VC), defined as the mean diameter of the corneal vessels.

RESULTS
There were no severe adverse events following the use of topical pazopanib. Compared with the baseline visit, NA and VL showed a statistically significant decrease at week 3 (P = 0.02 and 0.01, respectively); and NA, IA, and VL statistically significantly decreased at week 12 (P = 0.03, 0.04, and <0.01, respectively). Visual acuity maintained without changes after the 12 week follow-up.

CONCLUSIONS
This preliminary study suggests that topical treatment with pazopanib 0.5% is safe, well tolerated, and may have a role as an alternative for the treatment of CNV (ClinicalTrials.gov number, NCT01257750).